错配修复蛋白1、错配修复蛋白2及细胞黏附分子变异体在卵巢上皮性癌中的表达及意义  

Expression and significance of mismatch repair protein I, mismatch repair Protein 2 and cellular adhesive molecular variants in ovarian epithelial carcinoma

作　　者：王丽娟 王允山[2] 彭俊华 王浩 顾磊 

机构地区：[1]枣庄矿业集团中心医院病理科,山东省枣庄277800 [2]山东大学医学院解剖教研室

出　　处：《中国基层医药》2015年第20期3152-3155,共4页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨人类错配修复蛋白1（MLH1）、错配修复蛋白2（MSH2）及细胞黏附分子变异体（C044v6）在卵巢上皮性癌中的表达及临床意义。方法应用免疫组织化学S-P法检测MLH1、MSH2及CD44v6在60例卵巢上皮性癌、35例卵巢交界性肿瘤和35例卵巢良性肿瘤组织中的表达。结果MLH1在卵巢上皮性癌和交界性肿瘤中的阳性表达率分别为43．33％（26／60）、48．57％（17／35），均明显低于于良性肿瘤阳性表达率的91．43％（32／35），差异有统计学意义（x2=20．16、15．31，均P〈0．05）。卵巢上皮性癌和交界性肿瘤MSH2的阳性表达率分别为38．33％（23／60）、51．43％（18／35），均明显低于良性肿瘤阳性表达率的88．57％（31／35），差异有统计学意义（x2=22．74、11．49，均P〈0．05）。MLH1的表达率在卵巢上皮性癌有无淋巴结转移组、高级别与低级别组比较有差异，但差异无统计学意义（X2：2．24、1．19，均P〉0．05）。MSH2的表达下调与卵巢上皮性癌的分化程度、有无淋巴结转移及临床分期密切相关（X2=5．22、7．86、4．38，均P〈0．05）。CD44v6在卵巢上皮性癌、交界性肿瘤和良性肿瘤中阳性表达率分别为78．33％（47／60）、54．29％（19／35）、17．14％（6／35），差异有统计学意义（0=33．55、10．52，均P〈0．05）。CD44v6与卵巢上皮性癌有无淋巴结转移及临床分期密切相关（X2=6．10、5．88，均P〈0．05）。结论MLH1、MSH2和CD44v6在卵巢上皮性癌的发生、进展、侵袭中起到重要调控作用，并是判断其预后的重要参考指标。Objective To explore the expression and clinical significance of human mismatch repair proteinl （MLHI） ,mismatch repair protein2（MSH2） and cellular adhesion molecular variants（CD44v6） in ovarian epithelial carcinoma. Methods The immunohistochemical S - P method was used to detect the expression levels of MLH1, MSH2 and CDd4v6 in 60 cases of ovarian epithelial carcinoma,35 cases of borderline ovarian tumor and 35 cases of ovarian benign tumor tissue. Results The positive expression rates of MLH1 in ovarian epithelial carcinoma and boundary tumor were 43.33% （26/60） ,48.57% （ 17/35 ）, which were significantly lower than 91.43% （ 32/35 ） of benign tumor （ X2 = 20.16,15.31, all P 〈 0.05 ）. The positive expression rates of MSI-I2 in ovarian epithelial carcinoma and boundary tumor were 38.33% （23/60）, 51.43% （ 18/35 ）, which were significantly lower than 88.57% （ 31/35 ） of benign tumor （x2 = 22.74,11.49, all P 〈 0.05 ）. MLH1 expression rate in ovarian epithelial carcinoma with or without lymph node metastasis group, high level and low level had differences, but the differences were not statistically significant （x2 =2.24,1.19,all P 〉0.05）. The decreased expression of MSH2 was closely related to the differentiation degree of ovarian epithelial carcinoma, lymph node metastasis and clinical stage （X2 = 5.22,7.86, 4. 38, all P 〈 0.05 ）. The positive expression rates of CD44v6 in ovarian epithelial carcinoma tumors, boundary tumors and benign tumors were 78.33 % （47/60） ,54.29% （19/35）, 17.14% （6/35）, the differences were statistically significant （x2 = 33.55,10.52, all P 〈 0.05 ）. CD44v6 was closely related to lymph node metastasis of ovarian epithelial carcinoma and clinical stage （ x2 = 6.10,5.88, all P 〈 0.05 ）. Conclusion MLH1, MSH2 and CIM4v6 play important roles in the occurrence and development of ovarian epithelial carcinoma, and are important reference index to judge prognosis.

关 键 词：卵巢肿瘤 上皮 DNA错配修复蛋白Muts 细胞黏附分子变异体 卵巢上皮性癌 免疫化学 

分 类 号：R737.31[医药卫生—肿瘤]